Toby Talbot

Truro, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".

Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 10, 2026

Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 02, 2026

Real-world efficacy and toxicity of tebentafusp in metastatic uveal melanoma patients treated on the United Kingdom expanded access programme.

Real-world efficacy and toxicity of tebentafusp in metastatic uveal melanoma patients treated on the United Kingdom expanded access programme.

Journal: The oncologist

Published: February 27, 2026

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 24, 2026

Clinically relevant recurrence of basal cell carcinoma following primary treatment with hypofractionated kilovoltage radiotherapy: A single-centre retrospective review.

Clinically relevant recurrence of basal cell carcinoma following primary treatment with hypofractionated kilovoltage radiotherapy: A single-centre retrospective review.

Journal: The British journal of dermatology

Published: October 17, 2025

A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study).

A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study).

Journal: Future oncology (London, England)

Published: May 20, 2025

Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.

Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: March 31, 2025

CODAK: Real-World Clinical Outcomes of Patients With Unresectable, Stage III Non-Small Cell Lung Cancer Treated With Durvalumab After Chemoradiotherapy in the United Kingdom.

CODAK: Real-World Clinical Outcomes of Patients With Unresectable, Stage III Non-Small Cell Lung Cancer Treated With Durvalumab After Chemoradiotherapy in the United Kingdom.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: December 04, 2024

A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.

A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 25, 2024

Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis.

Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis.

Journal: Therapeutic advances in medical oncology

Published: May 20, 2024

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.

Journal: Lancet (London, England)

Published: December 14, 2022

Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood.

Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood.

Journal: Immunotherapy advances

Published: August 17, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026